The awards ceremony of the 19th edition of the Yearbook took place last Tuesday (20th), at the Unique Hotel, in São Paulo (SP)
Prati-Donaduzzi, the largest producer of generic drugs in Brazil *, is among the most outstanding companies in Brazil in 2018, according to Valor 1000 yearbook, elaborated by Valor Econômico newspaper. The awards ceremony of the 19th edition of the Yearbook took place last Tuesday (20th), at the Unique Hotel, in São Paulo (SP).
Last year, the company obtained net income of $ 69.9 million. The profitability of the industry based in Paraná was 12% higher compared to other companies in the pharmaceutical and cosmetic market, where Prati-Donaduzzi competed. In this category, the company occupies the sixth place among the most profitable pharmaceutical companies.
According to Eder Fernando Maffissoni, Prati-Donaduzzi CEO, the participation in the Yearbook is very important as it highlights the company's efforts to improve its processes.
"Being among the one thousand largest companies in Brazil for the eighth consecutive year, and also among the six companies regarding profitability in the sector, is a source of pride and highlights the structured growth", he said.
According to Maffissoni, the result comes from the well-planned strategic planning, investments in research, development and innovation, especially in the quality of the products and, above all, in the training of the team. "We remain confident, evolving solidly and always keeping an eye on the future", said the executive.
Growth
Maintaining its accelerated growth, Prati-Donaduzzi ended the first half of 2019 with 46 new drug presentations, totaling 354 products in its portfolio.
According to the CEO, the pharmaceutical company is in a constant growth process. “We want to be the owner of one of the largest generic portfolios in the country soon. And by 2022, we are projected to continue growing 15% per year”, said Maffissoni.
The pharmaceutical company has made investments in several areas in order to achieve these goals and to end the year with the production of 12 billion doses of generics. Among them, in process improvement, especially in research, innovation, acquisition of new equipment and hiring qualified labor force.
Research
To elaborate Valor 1000 ranking, companies were analyzed in 25 categories. Net revenue, profitability, current performance measurement criteria, and debt management were used as a parameter for ranking. The analysis was prepared in partnership with Serasa Experian and Getulio Vargas Foundation.
According to the survey, the participating companies grew. Revenue, in real terms, grew 12.9% in 2018 reaching almost $ 4 trillion. There was also a significant reduction in debt. Financial leverage, as measured by the ratio of net financial debt to Ebtida, fell by 0.3 percentage points returning to the pre-2013 economic crisis.
In addition to renowned entrepreneurs from different niches and economic sectors, the Minister of Economy, Paulo Guedes, and the president of the Chamber of Deputies, Rodrigo Maia, attended the award ceremony.
PRATI-DONADUZZI
Prati-Donaduzzi, the 100% Brazilian pharmaceutical industry is specialized in the development and production of generic drugs. Based in Toledo, western Paraná, Prati-Donaduzzi produces about 11.5 billion therapeutic doses per year and has about 4,300 employees. The company has one of the largest portfolios of generic drugs in Brazil* and aims to grow its sales and production capacity by 15% in 2019.
*IQVIA MAT JUN/2019 PMB + NRC Doses Terapêuticas
